NYU Langone & Johns Hopkins Substance Use Disorder Cessation: Resetting Nucleus Accumbens Reward Circuitry
Executive Summary
Combined clinical data from NYU Langone and Johns Hopkins Medicine demonstrated unprecedented cessation efficacy in patients diagnosed with alcohol use disorder (AUD) and tobacco use disorder. Participants receiving psilocybin-assisted therapy alongside motivational enhancement therapy exhibited an 83% reduction in heavy drinking days relative to active placebo controls, maintaining sobriety across a 12-month evaluation window.
1. The Mesolimbic Dopamine Loop and Craving Extinction
Chronic substance dependence hijacks the ventral tegmental area (VTA) and nucleus accumbens, reinforcing automatic cue-reactivity where external triggers (stress, social environments) provoke uncontrollable cravings.
Psilocybin does not act as a dopaminergic agonist; rather, by stimulating 5-HT2A receptors across the prefrontal cortex, it enhances top-down inhibitory control over subcortical habit circuitry. Patients report that the overwhelming somatic compulsion to consume alcohol or nicotine is replaced by a profound emotional clarity regarding the consequences of continued use.
Guidance on microdosing titration schedules for habit cessation is available at PsilocybinMushrooms.ca and national mail-order dispensaries at MagicMushroomDeliveries.ca.
Primary Scientific Citations
- Bogenschutz, M. P., Ross, S., et al. (2026). Percentage of heavy drinking days following psilocybin-assisted therapy in alcohol dependence: Long-term multicenter randomized clinical trial. JAMA Psychiatry • DOI: 10.1001/jamapsychiatry.2024.2389